Apellis Pharma

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Apellis Pharma reports strong Q1 revenue, eyes U.S. expansion

Apellis Pharma's Q1 2023 performance showcased strong revenue from SYFOVRE and EMPAVELI, with positive feedback and demand in the market.
While facing challenges like safety concerns and European commercialization, the company is focused on expanding market reach and driving awareness.
Opportunities lie in making SYFOVRE widely available, promoting patient education, and potential approval in Europe for further growth.

Apellis Pharma reports robust Q2 sales amidst safety event challenges

Apellis Pharma's Q2 performance highlighted strong sales, positive product efficacy, and proactive response to safety events
Despite challenges with rare safety events, the company's strengths in product credibility, manufacturing quality, and market acceptance shine through
Opportunities lie in enhancing physician education, exploring financing options, and leveraging positive efficacy evolution for market growth
Overall, Apellis Pharma's strategic measures position it well to navigate challenges, capitalize on opportunities, and maintain market confidence

Apellis Pharma reports mixed Q3 results, eyes European expansion

Apellis Pharma's Q3 performance showed strong revenue from key products but also highlighted the need for cost-saving measures. The company's focus on global expansion and product launches in Europe presents growth opportunities amidst market challenges.

Apellis Pharma reports strong Q4 earnings amidst market challenges

Apellis Pharma delivered strong financial results in Q4 2023, driven by the success of SYFOVRE and EMPAVELI in the U.S., while navigating challenges in the EU market and competitive landscape.
The company's strategic focus on patient access, market leadership, and R&D advancement positions it for continued growth and innovation in precision medicine, supported by robust engagement with medical communities.
Opportunities lie in expanding market share through bilateral treatments, advancing pipeline programs, and leveraging compliance and real-world data to strengthen Apellis Pharma's position as a leading provider of GA therapies.
Addressing challenges such as market competition, regulatory processes, and financial performance will be crucial for Apellis Pharma to sustain growth, optimize revenue, and drive profitability in the future.

Apellis Pharma reports robust Q1 performance and eyes expansion

Apellis Pharma (APLS) showcased strong financial performance and product success in Q1 2024, with plans for expansion and upcoming study data.
Despite challenges like a negative CHMP opinion and safety concerns, opportunities in education, expansion, and market penetration are on the horizon.
The company's commitment to shareholder value, financial stability, and milestone achievements sets a positive outlook for the future.

Apellis Pharma reports robust Q2 earnings, eyes market expansion

Apellis Pharma's Q2 performance reflects strong revenue growth and market leadership, supported by successful product sales and strategic initiatives.
While facing competition and challenges in market share retention, the company's focus on expansion and financial strength bode well for future growth.
Opportunities in new indications, market expansion, and pipeline development position Apellis Pharma for continued value creation for patients and shareholders.

Apellis Pharma reports robust Q3 performance amidst market challenges

Apellis Pharma's Q3 performance reflects strong demand for SYFOVRE and strategic initiatives to drive market share.
While facing challenges such as gross to net adjustments and market dynamics, the company remains optimistic about future growth opportunities.
By leveraging strengths in product efficacy and real-world data, Apellis Pharma aims to expand globally and enhance profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals said on Thursday a panel of the European drugs regulator was likely to vote against approving its chronic eye disease treatment, sending its shares down more than 20% in early trading.

Apellis says EU regulator may not approve its eye drug

Apellis said Thursday it expects European regulators to reject its eye disease drug, Syfovre. APLS stock tumbled below its 200-day line.

Apellis Crashes 21% As It Stares Down A Likely European Rejection

Apellis Pharmaceuticals Inc.'s stock APLS, +1.81% tumbled 14% early Thursday, after the company said it's been informed of a negative trend vote on the European marketing authorization application (MAA) for its treatment for an advanced form of age-related macular degeneration that's a leading cause of blindness. The company said it had an oral explanation meeting with the Europe Committee for Medicinal Products for Human Use of the European Medicines Agency on Dec. 13 regarding its MAA for pegcetacoplan as a treatment for geographic atrophy, or GA, and was then informed of the negative trend vote.

Apellis Pharmaceuticals' stock slides 14% after company gets negative trend vote for eye treatment in Europe

WALTHAM, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today an update on the ongoing review of its marketing authorization application (MAA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

WALTHAM, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi today presented post hoc data that reinforce the long-term efficacy and safety of EMPAVELI ® (pegcetacoplan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) for up to three years. The data were reported during an oral presentation at the American Society of Hematology (ASH) Annual Meeting.

EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting

Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe.

Apellis (APLS) Rides on Syfovre to Fuel Growth Amid Rivalry

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?

Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue?

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company will host a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:00 a.m. ET.

Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference

A Media Snippet accompanying this announcement is available by clicking on this link.

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in the reported quarter.

Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants Cedric Francois - Co-Founder and CEO Tim Sullivan - CFO Adam Townsend - CCO Caroline Baumal - CMO Meredith Kaya - SVP, IR Conference Call Participants Jonathan Miller - Evercore Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Phil Nadeau - TD Cowen Derek Archila - Wells Fargo Eliana Merle - UBS Akash Tewari - Jefferies Annabel Samimy - Stifel Financial Corp. Douglas Tsao - H.C. Wainwright Joseph Stringer - Needham & Company Operator Good morning ladies and gentlemen.

Apellis Pharmaceuticals, Inc. (APLS) Q3 2023 Earnings Call Transcript

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.75 per share a year ago.

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates

WALTHAM, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced its third quarter 2023 financial results and business highlights.

Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results

Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Apellis (APLS) This Earnings Season?

The consensus price target hints at a 51.9% upside potential for Apellis Pharmaceuticals, Inc. (APLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should Know

WALTHAM, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2023 financial results on Wednesday, November 1, 2023, at 8:00 a.m. ET.

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and DERBY studies evaluating SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). SYFOVRE is the only treatment approved for use beyond 12 months in GA, a chronic disease and leading cause of vision loss.

The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)

The mean of analysts' price targets for Apellis Pharmaceuticals, Inc. (APLS) points to a 67.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Apellis Pharmaceuticals, Inc. (APLS)? Wall Street Analysts Think 67.65%

Apellis' (APLS) shares rise as it provides third-quarter 2023 preliminary revenues guidance for Syfovre, approved for the treatment of geographic atrophy.

Apellis (APLS) Provides Syfovre Q3 Preliminary Revenues Guidance

Apellis Pharmaceuticals Inc (NASDAQ:APLS) stock is enjoying a boost today after an upgrade from J.P.

Pharma Stock Upgraded on Eye Disorder Drug Sales

WALTHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today provided an update on the launch of SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023

Apellis (APLS) receives the FDA approval for Empaveli Injector, a self-administred on-body device, to treat patients with paroxysmal nocturnal hemoglobinuria.

Apellis' (APLS) Empaveli Injector Gets FDA Nod for PNH

WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI® Injector. The EMPAVELI Injector is a compact, single-use, on-body device designed to enhance self-administration of EMPAVELI (pegcetacoplan), which is approved for adults with paroxysmal nocturnal hemoglobinuria (PNH).

Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

NEW YORK , Oct. 2, 2023 /PRNewswire/ -- Attention Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ: APLS) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between January 28, 2021 and July 28, 2023. If you suffered a loss on your investment in Apellis, contact us about potential recovery by using the link below.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023

LOS ANGELES, CA / ACCESSWIRE / October 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ:APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 28, 2021 and July 28, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 2, 2023.

News for Apellis Pharma Stock (APLS)